Skip to main content

Waters Corp (WAT)

Health Services Health Care
Stock AI

Financial Metrics

Price to Earnings246.1x
Revenue Growth (1Y)52.47%
Debt to Equity0.34x

Strengths

Stock Chart

Valuation

Waters Corp is overvalued

News

All
Press Releases
News
Filings
10-Q Quarterly Report for 2026 Q2
August 11, 202610-Q Quarterly Report for 2026 Q2
 Waters Corporation (NYSE: WAT) Reports Second Quarter 2026 Financial Results
August 04, 2026 Waters Corporation (NYSE: WAT) Reports Second Quarter 2026 Financial Results
 Waters Launches Industry's Most Sensitive and Robust Clinical IVD System with Xevo TQ Absolute XR IVD Mass Spectrometer
July 27, 2026 Waters Launches Industry's Most Sensitive and Robust Clinical IVD System with Xevo TQ Absolute XR IVD Mass Spectrometer
 Waters Corporation Schedules Second Quarter 2026 Earnings Conference Call
July 02, 2026 Waters Corporation Schedules Second Quarter 2026 Earnings Conference Call
 IMU Biosciences Selects Waters to Advance Breakthrough AI Immune Mapping Platform to Transform Early Diagnosis, Monitoring, and Precision Medicine
June 24, 2026 IMU Biosciences Selects Waters to Advance Breakthrough AI Immune Mapping Platform to Transform Early Diagnosis, Monitoring, and Precision Medicine
 Waters Launches Coin Cell Differential Scanning Calorimeter (DSC) to Advance Battery Safety with Integrated Thermal, Evolved Gas, and Electrochemical Analysis
June 09, 2026 Waters Launches Coin Cell Differential Scanning Calorimeter (DSC) to Advance Battery Safety with Integrated Thermal, Evolved Gas, and Electrochemical Analysis
 Waters Launches Industry-First Reversed-Phase Bioseparation Columns to Deliver Up to 3x Faster GLP-1 Characterization and 2x Faster LNP Component Analysis
June 08, 2026 Waters Launches Industry-First Reversed-Phase Bioseparation Columns to Deliver Up to 3x Faster GLP-1 Characterization and 2x Faster LNP Component Analysis
 Waters Announces FDA 510(k) Clearance of BD BACTEC FXI Culture System, Enabling Broader Access to Bloodstream Infection Diagnostics
June 03, 2026 Waters Announces FDA 510(k) Clearance of BD BACTEC FXI Culture System, Enabling Broader Access to Bloodstream Infection Diagnostics
 Waters Unveils Cyclic IMS P20 MS: The New Benchmark in Structural and Spatial Omics
June 01, 2026 Waters Unveils Cyclic IMS P20 MS: The New Benchmark in Structural and Spatial Omics
 Waters Introduces Unrivaled Sensitivity and Speed to Benchtop HRMS with Xevo MRT P10 MS, Accelerating Multiomics Research
June 01, 2026 Waters Introduces Unrivaled Sensitivity and Speed to Benchtop HRMS with Xevo MRT P10 MS, Accelerating Multiomics Research
 Waters Corporation to Present at the Jefferies Global Healthcare Conference
May 18, 2026 Waters Corporation to Present at the Jefferies Global Healthcare Conference
10-Q Quarterly Report for 2026 Q1
May 12, 202610-Q Quarterly Report for 2026 Q1
Waters CEO highlights China as key innovation source in the biopharma market
May 05, 2026Waters CEO highlights China as key innovation source in the biopharma market
 Waters Corporation (NYSE: WAT) Reports First Quarter 2026 Financial Results
May 05, 2026 Waters Corporation (NYSE: WAT) Reports First Quarter 2026 Financial Results
 Waters Corporation Schedules First Quarter 2026 Earnings Conference Call
April 20, 2026 Waters Corporation Schedules First Quarter 2026 Earnings Conference Call
 Waters Announces CE Mark for Next-Generation Fully Automated BD BACTEC FXI Culture System for Bloodstream Infection Diagnosis
April 15, 2026 Waters Announces CE Mark for Next-Generation Fully Automated BD BACTEC FXI Culture System for Bloodstream Infection Diagnosis
 Waters Debuts Industry-First Extended-Range MALS Detector for UHPLC/UPLC, Powering Rapid Characterization of Large Molecules
April 14, 2026 Waters Debuts Industry-First Extended-Range MALS Detector for UHPLC/UPLC, Powering Rapid Characterization of Large Molecules
Waters Stock Shoots Higher As FDA Clears At-Home Cervical Cancer Screening Kit
April 08, 2026Waters Stock Shoots Higher As FDA Clears At-Home Cervical Cancer Screening Kit
 Waters Announces FDA Clearance of the Most Comprehensive At-Home Cervical Cancer Screening Tool, the Onclarity HPV Self-Collection Kit and FDA-Approved HPV Assay
April 08, 2026 Waters Announces FDA Clearance of the Most Comprehensive At-Home Cervical Cancer Screening Tool, the Onclarity HPV Self-Collection Kit and FDA-Approved HPV Assay
 Waters Prices Offering of Senior Notes
March 18, 2026 Waters Prices Offering of Senior Notes
 Waters Flagship ARES‑G3 Rheometer Sets New Benchmark for Data Quality at Breakthrough Speed
March 09, 2026 Waters Flagship ARES‑G3 Rheometer Sets New Benchmark for Data Quality at Breakthrough Speed
 Waters Corporation to Present at the TD Cowen Health Care Conference
February 23, 2026 Waters Corporation to Present at the TD Cowen Health Care Conference
10-K Annual Report for 2025 FY
February 23, 202610-K Annual Report for 2025 FY
 Waters Introduces Next-Generation Microflow LC Columns with MaxPeak Premier Technology, Delivering Higher Sensitivity with Lower Sample and Solvent Usage
February 17, 2026 Waters Introduces Next-Generation Microflow LC Columns with MaxPeak Premier Technology, Delivering Higher Sensitivity with Lower Sample and Solvent Usage
What's Going On With Becton Dickinson Stock Tuesday?
February 10, 2026What's Going On With Becton Dickinson Stock Tuesday?
Software Stocks Rebound, Silver Rallies 6% To $82: What's Moving Markets Monday?
February 09, 2026Software Stocks Rebound, Silver Rallies 6% To $82: What's Moving Markets Monday?
Why Is Waters Stock Sinking Monday?
February 09, 2026Why Is Waters Stock Sinking Monday?
Becton Dickinson Slashes Profit Outlook Post-Spinoff
February 09, 2026Becton Dickinson Slashes Profit Outlook Post-Spinoff
 Waters Completes Combination with BD's Biosciences & Diagnostic Solutions Businesses
February 09, 2026 Waters Completes Combination with BD's Biosciences & Diagnostic Solutions Businesses
 Waters Corporation (NYSE: WAT) Reports Fourth Quarter and Full-Year 2025 Financial Results
February 09, 2026 Waters Corporation (NYSE: WAT) Reports Fourth Quarter and Full-Year 2025 Financial Results
 Waters Shareholders Approve Combination with BD's Biosciences & Diagnostic Solutions Business
January 27, 2026 Waters Shareholders Approve Combination with BD's Biosciences & Diagnostic Solutions Business
 Waters Corporation Schedules Fourth Quarter 2025 Earnings Conference Call
January 20, 2026 Waters Corporation Schedules Fourth Quarter 2025 Earnings Conference Call
Waters-Becton Dickinson Deal May Deliver Bigger Gains Than Expected: Analyst
January 06, 2026Waters-Becton Dickinson Deal May Deliver Bigger Gains Than Expected: Analyst
 Waters Corporation to Present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026
December 23, 2025 Waters Corporation to Present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026
 Waters Corporation to Present at the Jefferies Global Healthcare Conference in London
November 11, 2025 Waters Corporation to Present at the Jefferies Global Healthcare Conference in London
 Waters Boosts Lab Productivity and Sample Throughput with Launch of its Charged Aerosol Detector Designed for Empower Software
November 11, 2025 Waters Boosts Lab Productivity and Sample Throughput with Launch of its Charged Aerosol Detector Designed for Empower Software
Becton Dickinson Sees High Single-Digit Profit Growth Ahead, Plans Share Buybacks From Waters Deal
November 06, 2025Becton Dickinson Sees High Single-Digit Profit Growth Ahead, Plans Share Buybacks From Waters Deal
 Waters Corporation (NYSE: WAT) Reports Third Quarter 2025 Financial Results
November 04, 2025 Waters Corporation (NYSE: WAT) Reports Third Quarter 2025 Financial Results
10-Q Quarterly Report for 2025 Q3
November 04, 202510-Q Quarterly Report for 2025 Q3
 Waters Launches Charge Detection Mass Spectrometry Technology to Accelerate the Development of Next-Generation Biotherapeutics
October 13, 2025 Waters Launches Charge Detection Mass Spectrometry Technology to Accelerate the Development of Next-Generation Biotherapeutics
 Waters Corporation Schedules Third Quarter 2025 Earnings Conference Call
October 01, 2025 Waters Corporation Schedules Third Quarter 2025 Earnings Conference Call
 Waters Corporation to Present at the Wells Fargo Healthcare Conference
August 26, 2025 Waters Corporation to Present at the Wells Fargo Healthcare Conference
10-Q Quarterly Report for 2025 Q2
August 04, 202510-Q Quarterly Report for 2025 Q2
Schlumberger, Stellantis And ASML Holding Are Among Top 10 Large Cap Losers Last Week (July 14-July 18): Are The Others In Your Portfolio?
July 20, 2025Schlumberger, Stellantis And ASML Holding Are Among Top 10 Large Cap Losers Last Week (July 14-July 18): Are The Others In Your Portfolio?
Becton's Biosciences And Diagnostics Arm Slated To Join Waters In $17.5 Billion Merger
July 14, 2025Becton's Biosciences And Diagnostics Arm Slated To Join Waters In $17.5 Billion Merger
Stocks Fall On Trade Concerns, Oil And Gold Rally: What's Driving Markets Tuesday?
May 06, 2025Stocks Fall On Trade Concerns, Oil And Gold Rally: What's Driving Markets Tuesday?
10-Q Quarterly Report for 2025 Q1
May 06, 202510-Q Quarterly Report for 2025 Q1
This Waters Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday
March 26, 2025This Waters Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday
10-K Annual Report for 2024 FY
February 25, 202510-K Annual Report for 2024 FY
10-Q Quarterly Report for 2024 Q3
November 01, 202410-Q Quarterly Report for 2024 Q3
10-Q Quarterly Report for 2024 Q2
July 31, 202410-Q Quarterly Report for 2024 Q2
10-Q Quarterly Report for 2024 Q1
May 07, 202410-Q Quarterly Report for 2024 Q1
10-K Annual Report for 2023 FY
February 27, 202410-K Annual Report for 2023 FY
10-Q Quarterly Report for 2023 Q3
November 07, 202310-Q Quarterly Report for 2023 Q3
10-Q Quarterly Report for 2023 Q2
August 02, 202310-Q Quarterly Report for 2023 Q2
10-Q Quarterly Report for 2023 Q1
May 09, 202310-Q Quarterly Report for 2023 Q1
10-K Annual Report for 2022 FY
February 27, 202310-K Annual Report for 2022 FY
10-Q Quarterly Report for 2022 Q3
November 03, 202210-Q Quarterly Report for 2022 Q3
10-Q Quarterly Report for 2022 Q2
August 04, 202210-Q Quarterly Report for 2022 Q2
10-Q Quarterly Report for 2022 Q1
May 05, 202210-Q Quarterly Report for 2022 Q1
10-K Annual Report for 2021 FY
February 24, 202210-K Annual Report for 2021 FY
10-Q Quarterly Report for 2021 Q3
November 04, 202110-Q Quarterly Report for 2021 Q3

A. Company Overview

Waters Corporation stands as a global leader in analytical instruments and software, specializing in chromatographic and mass spectrometric technologies, thermal analysis, rheometry, and calorimetry for over 65 years. Headquartered in Milford, Massachusetts, the company has established its presence with approximately 7,900 employees operating in over 35 countries, while its products are available in more than 100 countries globally. Waters Corporation designs, manufactures, sells, and services high-performance analytical systems, including high-performance liquid chromatography (HPLC), ultra-performance liquid chromatography (UPLC), mass spectrometry (MS) technology, and thermal analysis equipment through its TA Instruments brand. These analytical technologies are integral in various fields such as pharmaceutical, clinical, biochemical, industrial, nutritional safety, environmental analysis, academic research, and government applications.

Waters Corporation has evolved through significant technological advancements and strategic acquisitions, enhancing its portfolio over time. Key acquisitions include TA Instruments in 1996, Micromass Limited in 1997, and Wyatt Technology in 2023. The acquisition of Wyatt Technology, known for its pioneering work in innovative light scattering techniques and fractionation instruments, aims to bolster Waters’ capabilities in the large molecule market.

B. Business Segments

Waters Corporation's operations can be categorized primarily into two significant segments: Waters and TA (TA Instruments).

Waters Segment

The Waters segment focuses on the design, manufacture, and sale of HPLC and MS systems along with associated consumable products such as chromatography columns and other precision chemistry consumables. With its stronghold in the pharmaceutical and life sciences markets, this segment addresses critical applications including drug discovery, clinical trial testing, and environmental testing.

TA Segment

The TA segment specializes in developing thermal analysis, rheometry, and calorimetry instruments, essential for evaluating the thermal properties of various materials in industries ranging from pharmaceuticals to electronics.

Both segments are integrated into a singular reporting category for financial purposes due to their similar economic characteristics and customer demographics.

C. Products and Markets

Waters Corporation's extensive range of products is designed to meet the diverse needs of analytical workflows across various industries.

High-Performance and Ultra-Performance Liquid Chromatography

HPLC serves as a fundamental analytical technique essential for identifying and analyzing chemical components across different materials. It is particularly significant in pharmaceutical research, quality control, and compliance testing. The introduction of ultra-performance liquid chromatography (UPLC) has brought advancements in speed and resolution of chemical separations, notably with systems like the ACQUITY UPLC, which allows for higher sensitivity in analysis and compatibility with existing workflows.

Key applications include:

  • Pharmaceutical Development: HPLC is crucial for drug characterization, potency verification, and manufacturing processes.
  • Environmental Testing: HPLC is employed in monitoring air and water purity.
  • Quality Assurance: Nutritional testing in food and beverages, along with compliance verification for safety standards.

Recent innovations in LC products, such as the ACQUITY Premier LC solution and the newly introduced DynaPro ZetaStar for nanoparticle analysis, showcase the company’s commitment to enhancing performance and functionality.

Mass Spectrometry and Liquid Chromatography-Mass Spectrometry

Waters Corporation is recognized for its robust portfolio of MS instruments, which are vital for compound identification, quantification, and structural elucidation. The MS systems are often integrated with LC systems, enhancing their analytical capabilities through advanced technologies like time-of-flight (ToF) and ion mobility spectrometry.

Noteworthy applications are found within:

  • Proteomics: Understanding disease mechanisms via protein analysis.
  • Clinical Testing: High-resolution detection for biomarker research.
  • Pharmaceutical Analysis: Comprehensive examination of drug compounds and contaminants.

Thermal Analysis, Rheometry, and Calorimetry

Instruments from the TA segment are pivotal in the characterization of materials across their thermal and physical properties. They contribute to the development processes in various sectors, including pharmaceuticals, polymers, and food safety.

Specific areas of focus include:

  • Material Stability Testing: Evaluating the behavior of materials under thermal stress.
  • Rheological Assessment: Understanding the flow properties and interaction behaviors of materials.

The ability to measure and predict material characteristics is crucial for product development in numerous industries.

D. Research and Development

Waters Corporation is dedicated to advancing its technological offerings through active research and development (R&D). With R&D expenditures reaching approximately $175 million in 2023, the company focuses on the continuous enhancement of existing products and the development of new innovations. The majority of R&D activities are centered at the Milford facility, with significant contributions from other sites specialized in mass spectrometry and materials characterization.

The company’s R&D efforts are bolstered by strategic collaborations with academic institutions and research organizations, exemplified by the establishment of a laboratory in Cambridge, Massachusetts, aimed at fostering community-driven scientific advancements.

E. Manufacturing and Distribution

Waters Corporation emphasizes high-quality production standards across its manufacturing facilities located primarily in the United States and Europe. The company’s production facilities maintain various certifications, including ISO 9001:2015 and ISO 13485:2016, ensuring compliance with stringent quality standards.

Key manufacturing sites include:

  • Milford, Massachusetts: Assembly of LC instruments.
  • Taunton, Massachusetts and Wexford, Ireland: Production of chromatography columns and consumables.
  • Wilmslow, England: Manufacturing of mass spectrometry instruments.

The company’s distribution strategy enables global access to its products while ensuring efficient supply chain management. Consistent quality control procedures are pivotal throughout the manufacturing process, which encompasses both in-house and outsourced operations.

F. Global Customers and Sales

Waters Corporation serves a wide array of customers, including multinational pharmaceutical companies, academic and research institutions, governmental agencies, and various industrial sectors. The pharmaceutical market constitutes the company’s largest sector, where ongoing investment in R&D and regulatory compliance drives demand for analytical technologies.

The sales structure comprises a large direct sales and service organization, providing comprehensive support and consultative services tailored to customer needs. With nearly 85 sales offices worldwide, Waters Corporation leverages its specialized workforce to sustain and enhance customer relationships while expanding its installed base of analytical instruments.

G. Competitive Landscape

The analytical instrumentation market is marked by intense competition, characterized by several established players. Key competitors include Agilent Technologies, Thermo Fisher Scientific, and Bruker Corporation, among others. Competitive dynamics hinge on product performance, reliability, and service capabilities, with ongoing technological advancements and diversified product lines influencing market positioning.

The consumables market, particularly chromatography columns, is fragmented, with numerous suppliers competing on parameters such as quality, reproducibility, and performance. Waters Corporation's ability to manufacture its own resins and specialty products is viewed as a significant competitive advantage.

H. Environmental Considerations

Waters Corporation is committed to maintaining compliance with environmental regulations across its operational footprint, emphasizing sustainability in product offerings and operational practices. The company conducts regular assessments to mitigate its environmental impact while advancing its carbon footprint reduction initiatives.

Annual sustainability reports highlight efforts concerning environmental management, demonstrating a proactive approach to climate change adaptation and social responsibility.

Stock Infos

SectorHealth Care
IndustryHealth Services
CEOUdit Batra, Ph. D.

Dividends

Copyright ©2026 Taurigo GmbH. All rights reserved.Taurigo GmbH provides no investment advice. Any analyses, research, ideas, prices, or other information contained on this website are provided as general market information for educational and entertainment purposes only, and do not constitute investment advice. We assume no responsibility for the accuracy, completeness or timeliness of any financial information contained on this site. In particular, we do not constitute an invitation to buy, sell or hold securities or other financial products. We shall not be liable for any loss or damage, including without limitation loss of profits, arising directly or indirectly from use of or reliance on the provided information. Before making any investment decision, you should consider whether it is suitable for your situation and obtain appropriate financial, tax and legal advice.